Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease

被引：0
|
作者：
Peter Lockwood
Wayne Ewy
David Hermann
Nick Holford
机构：
[1] Pfizer Global Research and Development,Department of Pharmacology and Clinical Pharmacology, School of Medicine
[2] deCODE genetics,undefined
[3] University of Auckland,undefined
来源：
Pharmaceutical Research | 2006年 / 23卷
关键词：
Alzheimer's disease; clinical trial simulation; pharmacokinetic pharmacodynamic model; trial design;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 26 条
  • [21] Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study
    Bentwich, Jonathan
    Dobronevsky, Evgenia
    Aichenbaum, Sergio
    Shorer, Ran
    Peretz, Ruth
    Khaigrekht, Michael
    Marton, Revital Gandelman
    Rabey, Jose M.
    JOURNAL OF NEURAL TRANSMISSION, 2011, 118 (03) : 463 - 471
  • [22] Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof-of-principle study and call to action
    Dubbelman, Mark A.
    Vromen, Eleonora M.
    Tijms, Betty M.
    Berkhof, Johannes
    Ottenhoff, Lois
    Vijverberg, Everard G. B.
    Prins, Niels D.
    van der Flier, Wiesje M.
    Sikkes, Sietske A. M.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2024, 10 (03)
  • [23] Aroylhydrazones constitute a promising class of ‘metal-protein attenuating compounds’ for the treatment of Alzheimer’s disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone
    Daphne S. Cukierman
    Elio Accardo
    Rosana Garrido Gomes
    Anna De Falco
    Marco C. Miotto
    Maria Clara Ramalho Freitas
    Mauricio Lanznaster
    Claudio O. Fernández
    Nicolás A. Rey
    JBIC Journal of Biological Inorganic Chemistry, 2018, 23 : 1227 - 1241
  • [24] Aroylhydrazones constitute a promising class of 'metal-protein attenuating compounds' for the treatment of Alzheimer's disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone
    Cukierman, Daphne S.
    Accardo, Elio
    Gomes, Rosana Garrido
    De Falco, Anna
    Miotto, Marco C.
    Ramalho Freitas, Maria Clara
    Lanznaster, Mauricio
    Fernandez, Claudio O.
    Rey, Nicolas A.
    JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2018, 23 (08): : 1227 - 1241
  • [25] Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study
    Jerneren, Fredrik
    Cederholm, Tommy
    Refsum, Helga
    Smith, A. David
    Turner, Cheryl
    Palmblad, Jan
    Eriksdotter, Maria
    Hjorth, Erik
    Faxen-Irving, Gerd
    Wahlund, Lars-Olof
    Schultzberg, Marianne
    Basun, Hans
    Freund-Levi, Yvonne
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 69 (01) : 189 - 197
  • [26] Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimer's Disease Cooperative Study -Sponsored DHA Clinical Trial
    Tomaszewski, Natalie
    He, Xulei
    Solomon, Victoria
    Lee, Mitchell
    Mack, Wendy J.
    Quinn, Joseph F.
    Braskie, Meredith N.
    Yassine, Hussein N.
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 74 (03) : 975 - 990
123